All‐cause mortality · bleeding patients or at risk of severe bleeding
It is very uncertain whether fibrinogen concentrate changes mortality compared with any comparator (very low certainty).
1 finding from 1 review
Incidence of allogenic blood transfusion Proportion of participants transfused with RBC, FFP, PLT and/or cryo · bleeding patients or at risk of severe bleeding
It is very uncertain whether fibrinogen concentrate changes incidence of allogenic blood transfusion Proportion of participants… compared with any comparator (very low certainty).
1 finding from 1 review
Thrombotic episodes (arterial and venous graft occlusion, pulmonary embolus, deep venous thrombosis) Proportion with event · bleeding patients or at risk of severe bleeding
It is very uncertain whether fibrinogen concentrate changes thrombotic episodes (arterial and venous graft occlusion, pulmonary… compared with any comparator (very low certainty).
1 finding from 1 review
ICU length of stay (general intensive care patients) · bleeding patients or at risk of severe bleeding
1 finding from 1 review
Re‐operation due to persistent bleeding Events during admission · bleeding patients or at risk of severe bleeding
It is very uncertain whether fibrinogen concentrate changes re‐operation due to persistent bleeding Events during admission compared with any comparator (very low certainty).
1 finding from 1 review
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa compared with placebo (moderate certainty).
1 finding from 1 review
Visual acuity · 5‐ to 8‐year‐old children with amblyopia
2 findings from 1 review
Change in distance BCVA in the amblyopic eye 12 months after cessation of treatment · 5‐ to 8‐year‐old children with amblyopia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant adherence to intervention · 5‐ to 8‐year‐old children with amblyopia
1 finding from 1 review
Proportion of participants experiencing an adverse event of permanent diplopia (double vision) Reports of diplopia across all measured time points · 5‐ to 8‐year‐old children with amblyopia
1 finding from 1 review
Change in the interocular difference in contrast sensitivity Any validated test, from baseline to 16 (± 2) weeks · 5‐ to 8‐year‐old children with amblyopia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Measurable change in stereopsis after 8 (± 2) weeks and 16 (± 2) weeks of intervention 'Real change' in stereopsis is defined as a change in stereoacuity of two or more octaves. · 5‐ to 8‐year‐old children with amblyopia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive function · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review
Behavioural and psychological symptoms of dementia (BPSD) · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review
Agitated or aggressive behaviours in dementia patients, measured on the Cohen‐Mansfield Agitation Inventory (CMAI) Scale (range 29 to 203, with 29 meaning no symptoms, and higher number of points indicating more severe symptoms)Â · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review